Xarelto Lawsuit Update: Lawsuits Allege that Drug was Improperly Marketed

October 02, 2015 – – BloodThinnerHelp.com reports on allegations made by current Xarelto lawsuits. Many of the lawsuits filed in the Xarelto multidistrict litigation, MDL, allege that Xarelto was marketed by its manufacturers as a safer alternative to other blood thinner drugs while in reality this was not true. For more detailed information on the Xarelto lawsuits, click here.

Xarelto was released onto the United States market in 2011 after receiving approval from the Food and Drug Administration, FDA, to treat atrial fibrillation, deep vein thrombosis, and to be used in patients who have recently undergone a hip or knee replacement surgery. After the drug was released onto the market, Xarelto’s manufacturers, Bayer AG and Janssen Pharmaceuticals, the pharmaceutical subdivision of Johnson&Johnson, began a very intense marketing campaign to market Xarelto to the public. Television commercials featuring popular athletes and well known public figures were aired and advertisements were placed in popular and well regarded medical journals. These advertisements touted the convenience of Xarelto, discussing Xarelto’s lack of blood monitoring, one size fits all dosing method, and stating that Xarelto does not require a restrictive diet.

Xarelto Lawsuits Allege Drug is Dangerous:

Xarelto is different from other blood thinners because it is part of a new class of drugs called Xa inhibitors. Xa inhibitors work by blocking the chemical in the blood that is responsible for making the blood clot, thrombin. By blocking thrombin, Xarelto leaves the blood with no way to clot. This is especially dangerous because there is no antidote for the anticoagulant effects of Xarelto, so if a patient experiences an internal bleed, there is no way to stop the blood short of extreme lifesaving measures. This is in sharp contrast to the situation a patient is in if they experience an internal bleed and are taking the traditional blood thinner Warfarin. If a patient bleeds internally while on Warfarin, a doctor can administer vitamin K and the blood will clot again. The lawsuits allege that Xarelto’s manufacturers were aware of this information and put the drug to market anyway. They also allege that the manufacturers failed to adequately inform patients and doctors about the true dangers of Xarelto usage.

“If the manufacturers of Xarelto did indeed know about the dangers of the drug, they deserve to be brought to justice.” Xarelto attorney Marc Goldich said, “We strongly encourage anybody who feels that they have been harmed from Xarelto to contact us immediately.”

For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Marc Goldich
866-425-8902
1500 Walnut Street, 4th Floor, Philadelphia, PA 19102.

ReleaseID: 60004528